Are shares of Ramsay Health Care Limited (ASX:RHC) a buy?

Is Ramsay Health Care Limited (ASX: RHC) a buy following the weakness in the company's share price?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share price of Australia's largest private hospital operator Ramsay Health Care Limited (ASX: RHC) has fallen 12% over the last 12 months, significantly underperforming the broader market's gain of 8%.

The former market darling has lagged the performance of other large-cap healthcare companies such as Cochlear Limited (ASX: COH), CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD).

With the share price hovering just above its 52-week low of $53.01, is it time to buy shares in Ramsay?

Slowing growth

The weakness in Ramsay's share price has occurred due to a number of factors, ranging from a forecast slowdown in growth domestically and difficult trading conditions in France and the UK.

Ramsay saw core earnings per share increase by 7% in FY18, missing its own initial forecast of 8% to 10% growth announced last August. The company's Australian operations remain the crown jewel in its portfolio with EBITDA rising by 12% in FY18. Ramsay expects volumes to continue to grow but at a slowing rate for FY19, as the industry battles falling private hospital participation rates that peaked in 2015.

The international operations of Ramsay remain a concern with EBITDAR in France and the UK falling by 1% and 10% respectively over the prior period due to a difficult tariff environment and a significant downturn in NHS volumes. The company expects trading conditions in the UK to remain challenging in FY19 and maintains a neutral outlook in France.

Ramsay will be impacted by higher interest and tax in FY19 with expected core EBITDA growth of 4% to 6% in FY19 to translate into earnings per share growth of 2%. This would see Ramsay post earnings per share of $2.85 in FY19, well below the consensus estimate of $3.11 from over a year ago.

The growth in earnings that management has forecast for FY19 is below the compound annual growth rate of 12.5% in earnings per share Ramsay has delivered over the last 4 years. The reduced expectations of future growth has resulted in a justifiable contraction in the company's premium valuation multiple.

Foolish takeaway

Ramsay is currently trading for $54.20, which prices the stock at around 19 times forward earnings. Interestingly, Ramsay is trading at a lower valuation than its rival Healthscope Ltd (ASX: HSO).

Ramsay is the leading operator in the private health space and I would expect the company to grow over the long-term via demographic tailwinds, brownfield expansions, and any possible acquisitions. Whilst there are a number of positives for the long-term, the upside in the near-term looks limited based on the operating environment, and in my view makes the current valuation seem appropriate.

Motley Fool contributor Tim Katavic owns shares of CSL Limited and Ramsay Health Care Limited. The Motley Fool Australia has recommended Cochlear Ltd., Ramsay Health Care Limited, and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »